For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Geron (GERN - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? One simple way to answer this question is to take a look at the year-to-date performance of GERN and the rest of the Medical group's stocks.
Geron is one of 903 individual stocks in the Medical sector. Collectively, these companies sit at #5 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. GERN is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for GERN's full-year earnings has moved 41.96% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Our latest available data shows that GERN has returned about 38.60% since the start of the calendar year. Meanwhile, stocks in the Medical group have gained about 3.22% on average. This means that Geron is performing better than its sector in terms of year-to-date returns.
Breaking things down more, GERN is a member of the Medical - Biomedical and Genetics industry, which includes 393 individual companies and currently sits at #87 in the Zacks Industry Rank. Stocks in this group have gained about 10.41% so far this year, so GERN is performing better this group in terms of year-to-date returns.
Going forward, investors interested in Medical stocks should continue to pay close attention to GERN as it looks to continue its solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Geron (GERN - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? One simple way to answer this question is to take a look at the year-to-date performance of GERN and the rest of the Medical group's stocks.
Geron is one of 903 individual stocks in the Medical sector. Collectively, these companies sit at #5 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. GERN is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for GERN's full-year earnings has moved 41.96% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Our latest available data shows that GERN has returned about 38.60% since the start of the calendar year. Meanwhile, stocks in the Medical group have gained about 3.22% on average. This means that Geron is performing better than its sector in terms of year-to-date returns.
Breaking things down more, GERN is a member of the Medical - Biomedical and Genetics industry, which includes 393 individual companies and currently sits at #87 in the Zacks Industry Rank. Stocks in this group have gained about 10.41% so far this year, so GERN is performing better this group in terms of year-to-date returns.
Going forward, investors interested in Medical stocks should continue to pay close attention to GERN as it looks to continue its solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on GERN - FREE